tiprankstipranks
Trending News
More News >
Palvella Therapeutics, Inc. (PVLA)
:PVLA
US Market

Palvella Therapeutics (PVLA) Stock Forecast & Price Target

Compare
632 Followers
See the Price Targets and Ratings of:

PVLA Analyst Ratings

Strong Buy
9Ratings
Strong Buy
9 Buy
0 Hold
0 Sell
Based on 9 analysts giving stock ratings to
Palvella
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PVLA Stock 12 Month Forecast

Average Price Target

$49.22
▲(87.65%Upside)
Based on 9 Wall Street analysts offering 12 month price targets for Palvella Therapeutics in the last 3 months. The average price target is $49.22 with a high forecast of $70.00 and a low forecast of $38.00. The average price target represents a 87.65% change from the last price of $26.23.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","26":"$26","41":"$41","56":"$56","71":"$71"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$70.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":49.22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$49.22</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$38.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,26,41,56,71],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2021","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.14,28.590769230769233,32.041538461538465,35.49230769230769,38.94307692307692,42.393846153846155,45.84461538461538,49.29538461538461,52.746153846153845,56.19692307692308,59.64769230769231,63.098461538461535,66.54923076923077,{"y":70,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.14,26.992307692307694,28.844615384615384,30.696923076923078,32.54923076923077,34.401538461538465,36.253846153846155,38.106153846153845,39.958461538461535,41.81076923076923,43.66307692307692,45.51538461538462,47.36769230769231,{"y":49.22,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.14,26.12923076923077,27.11846153846154,28.107692307692307,29.096923076923076,30.086153846153845,31.075384615384614,32.06461538461539,33.05384615384615,34.043076923076924,35.03230769230769,36.02153846153846,37.01076923076923,{"y":38,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.71,"date":1617235200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.71,"date":1619827200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.71,"date":1622505600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.71,"date":1627776000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.71,"date":1635724800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.71,"date":1640995200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.43,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.37,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.59,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.09,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$70.00Average Price Target$49.22Lowest Price Target$38.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Scotiabank Analyst forecast on PVLA
Louise ChenScotiabank
Scotiabank
$50
Buy
90.62%
Upside
Reiterated
06/10/25
Scotiabank Sticks to Its Buy Rating for Palvella Therapeutics (PVLA)
H.C. Wainwright Analyst forecast on PVLA
Andrew FeinH.C. Wainwright
H.C. Wainwright
$38
Buy
44.87%
Upside
Reiterated
05/16/25
Promising Outlook for Palvella Therapeutics: Buy Rating Affirmed by Andrew Fein Due to Phase 3 SELVA Trial Success and Strategic Market Position
Chardan Capital Analyst forecast on PVLA
Geulah LivshitsChardan Capital
Chardan Capital
$50
Buy
90.62%
Upside
Reiterated
05/15/25
Chardan Capital Sticks to Their Buy Rating for Palvella Therapeutics (PVLA)
Canaccord Genuity Analyst forecast on PVLA
Whitney IjemCanaccord Genuity
Canaccord Genuity
$53$52
Buy
98.25%
Upside
Reiterated
05/15/25
Palvella Therapeutics price target lowered to $52 from $53 at CanaccordPalvella Therapeutics price target lowered to $52 from $53 at Canaccord
TD Cowen Analyst forecast on PVLA
Ritu BaralTD Cowen
TD Cowen
$44
Buy
67.75%
Upside
Reiterated
05/15/25
Promising Outlook for Palvella Therapeutics: Buy Rating Backed by Strong Financials and Innovative QTORIN Platform
Cantor Fitzgerald Analyst forecast on PVLA
Joshua SchimmerCantor Fitzgerald
Cantor Fitzgerald
$30$70
Buy
166.87%
Upside
Reiterated
03/31/25
Palvella Therapeutics price target raised to $70 from $30 at Cantor FitzgeraldPalvella Therapeutics price target raised to $70 from $30 at Cantor Fitzgerald
Stifel Nicolaus Analyst forecast on PVLA
Annabel SamimyStifel Nicolaus
Stifel Nicolaus
$45
Buy
71.56%
Upside
Reiterated
03/31/25
Stifel reiterates Buy Rating on Palvella Therapeutics (PVLA)Stifel analyst Samimy Annabel reiterated a Buy rating and $45.00 price target on Palvella Therapeutics (NASDAQ: PVLA).
JonesTrading Analyst forecast on PVLA
Catherine NovackJonesTrading
JonesTrading
$45
Buy
71.56%
Upside
Initiated
03/24/25
Palvella Therapeutics initiated with a Buy at JonesResearchPalvella Therapeutics initiated with a Buy at JonesResearch
Lucid Capital Analyst forecast on PVLA
Dev PrasadLucid Capital
Lucid Capital
$49
Buy
86.81%
Upside
Initiated
03/18/25
Lucid Capital Markets starts Palvella Therapeutics (PVLA) at Buy, PT $49Lucid Capital Markets analyst Dev Prasad initiates coverage on Palvella Therapeutics (NASDAQ: PVLA) with a Buy rating and a price target of $49.00.
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Scotiabank Analyst forecast on PVLA
Louise ChenScotiabank
Scotiabank
$50
Buy
90.62%
Upside
Reiterated
06/10/25
Scotiabank Sticks to Its Buy Rating for Palvella Therapeutics (PVLA)
H.C. Wainwright Analyst forecast on PVLA
Andrew FeinH.C. Wainwright
H.C. Wainwright
$38
Buy
44.87%
Upside
Reiterated
05/16/25
Promising Outlook for Palvella Therapeutics: Buy Rating Affirmed by Andrew Fein Due to Phase 3 SELVA Trial Success and Strategic Market Position
Chardan Capital Analyst forecast on PVLA
Geulah LivshitsChardan Capital
Chardan Capital
$50
Buy
90.62%
Upside
Reiterated
05/15/25
Chardan Capital Sticks to Their Buy Rating for Palvella Therapeutics (PVLA)
Canaccord Genuity Analyst forecast on PVLA
Whitney IjemCanaccord Genuity
Canaccord Genuity
$53$52
Buy
98.25%
Upside
Reiterated
05/15/25
Palvella Therapeutics price target lowered to $52 from $53 at CanaccordPalvella Therapeutics price target lowered to $52 from $53 at Canaccord
TD Cowen Analyst forecast on PVLA
Ritu BaralTD Cowen
TD Cowen
$44
Buy
67.75%
Upside
Reiterated
05/15/25
Promising Outlook for Palvella Therapeutics: Buy Rating Backed by Strong Financials and Innovative QTORIN Platform
Cantor Fitzgerald Analyst forecast on PVLA
Joshua SchimmerCantor Fitzgerald
Cantor Fitzgerald
$30$70
Buy
166.87%
Upside
Reiterated
03/31/25
Palvella Therapeutics price target raised to $70 from $30 at Cantor FitzgeraldPalvella Therapeutics price target raised to $70 from $30 at Cantor Fitzgerald
Stifel Nicolaus Analyst forecast on PVLA
Annabel SamimyStifel Nicolaus
Stifel Nicolaus
$45
Buy
71.56%
Upside
Reiterated
03/31/25
Stifel reiterates Buy Rating on Palvella Therapeutics (PVLA)Stifel analyst Samimy Annabel reiterated a Buy rating and $45.00 price target on Palvella Therapeutics (NASDAQ: PVLA).
JonesTrading Analyst forecast on PVLA
Catherine NovackJonesTrading
JonesTrading
$45
Buy
71.56%
Upside
Initiated
03/24/25
Palvella Therapeutics initiated with a Buy at JonesResearchPalvella Therapeutics initiated with a Buy at JonesResearch
Lucid Capital Analyst forecast on PVLA
Dev PrasadLucid Capital
Lucid Capital
$49
Buy
86.81%
Upside
Initiated
03/18/25
Lucid Capital Markets starts Palvella Therapeutics (PVLA) at Buy, PT $49Lucid Capital Markets analyst Dev Prasad initiates coverage on Palvella Therapeutics (NASDAQ: PVLA) with a Buy rating and a price target of $49.00.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Palvella Therapeutics

1 Month
xxx
Success Rate
3/3 ratings generated profit
100%
Average Return
+23.27%
reiterated a xxx
rating 28 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +23.27% per trade.
3 Months
xxx
Success Rate
5/5 ratings generated profit
100%
Average Return
+66.92%
reiterated a xxx
rating 27 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +66.92% per trade.
1 Year
Andrew FeinH.C. Wainwright
Success Rate
5/5 ratings generated profit
100%
Average Return
+67.20%
reiterated a buy rating 27 days ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +67.20% per trade.
2 Years
xxx
Success Rate
5/5 ratings generated profit
100%
Average Return
+67.20%
reiterated a xxx
rating 27 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +67.20% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PVLA Analyst Recommendation Trends

Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
9
15
19
19
12
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
9
15
19
19
12
In the current month, PVLA has received 12 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. PVLA average Analyst price target in the past 3 months is 49.22.
Each month's total comprises the sum of three months' worth of ratings.

PVLA Financial Forecast

PVLA Earnings Forecast

The previous quarter’s earnings for PVLA were -$0.74.
The previous quarter’s earnings for PVLA were -$0.74.

PVLA Sales Forecast

Currently, no sales data available.
Currently, no sales data available.

PVLA Stock Forecast FAQ

What is PVLA’s average 12-month price target, according to analysts?
Based on analyst ratings, Palvella Therapeutics, Inc.’s 12-month average price target is 49.22.
    What is PVLA’s upside potential, based on the analysts’ average price target?
    Palvella Therapeutics, Inc. has 87.65% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is PVLA a Buy, Sell or Hold?
          Palvella Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Palvella Therapeutics, Inc.’s price target?
            The average price target for Palvella Therapeutics, Inc. is 49.22. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $70.00 ,the lowest forecast is $38.00. The average price target represents 87.65% Increase from the current price of $26.23.
              What do analysts say about Palvella Therapeutics, Inc.?
              Palvella Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of PVLA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis